The introduction of troglitazone, a potent antidiabetic agent, marked a notable chapter in the treatment of type 2 diabetes. However, its discontinuation from the market due to serious hepatotoxicity spurred extensive investigation into related thiazolidinediones. Later pioglitazone and rosiglitazone emerged, offering akin mechanisms of action –